Federated Hermes Inc. Sells 7,174 Shares of West Pharmaceutical Services, Inc. $WST

Federated Hermes Inc. cut its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 224,667 shares of the medical instruments supplier’s stock after selling 7,174 shares during the quarter. Federated Hermes Inc.’s holdings in West Pharmaceutical Services were worth $49,157,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SYM FINANCIAL Corp increased its position in West Pharmaceutical Services by 5.1% during the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 50 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of West Pharmaceutical Services by 4.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock worth $288,000 after purchasing an additional 51 shares during the period. MJP Associates Inc. ADV increased its position in shares of West Pharmaceutical Services by 2.7% during the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock valued at $431,000 after buying an additional 52 shares during the period. Horizon Investments LLC increased its position in shares of West Pharmaceutical Services by 5.8% during the first quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $234,000 after buying an additional 57 shares during the period. Finally, Pallas Capital Advisors LLC raised its stake in West Pharmaceutical Services by 1.0% in the second quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock worth $1,386,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the topic of a number of research analyst reports. KeyCorp upped their target price on West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, October 24th. UBS Group lifted their price target on West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Rothschild & Co Redburn started coverage on West Pharmaceutical Services in a report on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective for the company. Evercore ISI raised their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Finally, Redburn Partners set a $311.00 target price on shares of West Pharmaceutical Services in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $343.36.

West Pharmaceutical Services Trading Down 4.1%

West Pharmaceutical Services stock opened at $268.86 on Tuesday. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The business’s fifty day simple moving average is $273.87 and its two-hundred day simple moving average is $248.73. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90. The company has a market capitalization of $19.34 billion, a price-to-earnings ratio of 39.83, a price-to-earnings-growth ratio of 4.33 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.29. The firm had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.West Pharmaceutical Services’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, equities analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.